IN BRIEF:

RECOMMENDATION
The CADTH Canadian Drug Expert Committee (CDEC) recommends that tenofovir alafenamide (TAF) be reimbursed for the treatment of chronic hepatitis B in adults with compensated liver disease, if the following condition is met:

CONDITION:
The drug plan cost of TAF should not exceed that of the lowest-cost preparation of tenofovir disoproxil fumarate (TDF).

Read more:Ā https://www.cadth.ca/tenofovir-alafenamide